New hope for stubborn heart condition? drug trial targets double trouble

This study is testing if adding the medication sacubitril-valsartan to standard care helps people with a specific type of heart failure (where the heart pumps normally but doesn't relax well) who also have a leaky mitral valve. About 84 participants will be randomly assigned to receive either the new drug plus standard care or standard care alone for six months. Researchers will measure changes in heart and lung function during exercise, the severity of the valve leak, and how patients feel.